Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma
JMIR Cancer · 05.11.2026 · 12 · e95949-e95949
DOI: 10.2196/95949 ↗Kurz gefasst
Fachartikel in der Zeitschrift JMIR Cancer, online erschienen am 05.11.2026. Verfasst von Cindy Varga und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, Uni…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Bispecific antibodies are novel immunotherapies approved for the treatment of patients with relapsed or refractory multiple myeloma (MM). While these therapies induce deep and durable responses, they are associated with adverse events, such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, that require specific protocols for monitoring, prevention, and treatment. Due to the potential risk of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, current US labeling recommends inpatient administration during step-up dosing of bispecific antibodies, which typically occurs in academic centers and can often restrict the number of patients that can be treated. The administration of bispecific antibodies in the outpatient and community setting can enhance the patient experience and reduce resource use, which is a barrier to the widespread uptake of these treatments. With bispecific antibodies being evaluated in earlier lines of therapy for MM, the broader use of these agents will underscore the need for more accessible and less resource-intensive options that ensure safe outpatient administration. In this Viewpoint, we aim to provide practical recommendations built from our own real-world perspectives and case examples for institutions seeking to implement remote patient monitoring (RPM) strategies to support the outpatient dosing of bispecific antibodies in patients with MM. We discuss how the use of RPM has the potential to improve adverse event detection and management, improve patient outcomes, and decrease resource use and costs. While specific approaches will vary based on the needs of each treatment center, our experiences suggest that RPM implementation can be safe and feasible for both academic and community practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, United States, 1 980-442-4363.
- Department of Medical Oncology, Highlands Oncology Group, Fayetteville, AR, United States.
Zitieren
APA
Varga, C., & Schaefer, E. (2026). Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma. JMIR Cancer, 12, e95949-e95949. https://doi.org/10.2196/95949
Vancouver
Varga C, Schaefer E. Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma. JMIR Cancer. 2026;12:e95949-e95949. doi:10.2196/95949
BibTeX
@article{Varga2026,
author = {Varga, Cindy and Schaefer, Eric},
title = {Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma},
journal = {JMIR Cancer},
year = {2026},
volume = {12},
pages = {e95949--e95949},
doi = {10.2196/95949}
}
EUVIMED